Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Nov;62(5):786–790. doi: 10.1038/bjc.1990.380

Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels.

H Sigurdsson 1, B Baldetorp 1, A Borg 1, M Dalberg 1, M Fernö 1, D Killander 1, H Olsson 1, J Ranstam 1
PMCID: PMC1971535  PMID: 2245171

Abstract

The use of continuous prognostic variables is clinically impractical, and arbitrarily chosen cut-off points can result in a loss of prognostic information. Here we report findings from a study of primary breast cancer, showing how the prognostic value of the fraction of cells in the S-phase of the cell cycle (SPF), as measured by flow cytometry, can be affected by the SPF cut-off level(s) adopted. It was possible to evaluate the SPF in 566 (94%) of 603 consecutive cases where fresh frozen specimens were available in a tumour bank at our department. Clinically, all patients were without distant spread at the time of diagnosis, and the median duration of follow-up was 4 years. Using different survival end-points and chi 2 values for each cut-off level, two optimal cut-off points, at the 7% and 12% levels, were consistently obtained for the SPF. Furthermore, both disease-free survival and the relative risk of recurrence exhibited a non-linear relationship with SPF values; the curves implied that the prognosis was better among patients with SPF values about 2-5% than in patients with lower SPF values (parabolic shape), though the relationship with higher SPF values approached linearity. The non-linearity of the curves is incompatible with the general use of the median SPF as a prognostic cut-off value. An alternative procedure might be to use two cut-off levels, one to distinguish patients with the lowest SPF values (i.e. within the parabolic survival curve) from those with higher values (i.e. with a survival curve approaching linearity), the other to distinguish between patients with intermediate SPF values and those with high values (i.e. within the almost linear part of the survival curve). The 7% and 12% obtained here would be suitable for this purpose. We conclude that prognostic information can be gained by dividing the SPF into three prognostic categories (less than 7.0%, 7.0-11.9% and greater than or equal to 12%), instead of using the median SPF level.

Full text

PDF
786

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abel U., Berger J., Wiebelt H. CRITLEVEL: an exploratory procedure for the evaluation of quantitative prognostic factors. Methods Inf Med. 1984 Jul;23(3):154–156. [PubMed] [Google Scholar]
  2. Baisch H., Göhde W., Linden W. A. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys. 1975 Jun 13;12(1):31–39. doi: 10.1007/BF02339807. [DOI] [PubMed] [Google Scholar]
  3. Baldetorp B., Dalberg M., Holst U., Lindgren G. Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm. Cytometry. 1989 Nov;10(6):695–705. doi: 10.1002/cyto.990100605. [DOI] [PubMed] [Google Scholar]
  4. Clark G. M., Dressler L. G., Owens M. A., Pounds G., Oldaker T., McGuire W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989 Mar 9;320(10):627–633. doi: 10.1056/NEJM198903093201003. [DOI] [PubMed] [Google Scholar]
  5. Courdi A., Héry M., Chauvel P., Gioanni J., Namer M., Demard F. Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level. Br J Cancer. 1988 Jul;58(1):88–90. doi: 10.1038/bjc.1988.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Courdi A., Héry M., Dahan E., Gioanni J., Abbes M., Monticelli J., Ettore F., Moll J. L., Namer M. Factors affecting relapse in node-negative breast cancer. A multivariate analysis including the labeling index. Eur J Cancer Clin Oncol. 1989 Feb;25(2):351–356. doi: 10.1016/0277-5379(89)90029-1. [DOI] [PubMed] [Google Scholar]
  7. Fisher B., Bauer M., Wickerham D. L., Redmond C. K., Fisher E. R., Cruz A. B., Foster R., Gardner B., Lerner H., Margolese R. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983 Nov 1;52(9):1551–1557. doi: 10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  8. Kallioniemi O. P., Blanco G., Alavaikko M., Hietanen T., Mattila J., Lauslahti K., Lehtinen M., Koivula T. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. Cancer. 1988 Nov 15;62(10):2183–2190. doi: 10.1002/1097-0142(19881115)62:10<2183::aid-cncr2820621019>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  9. Lee G. M., Thornthwaite J. T., Rasch E. M. Picogram per cell determination of DNA by flow cytofluorometry. Anal Biochem. 1984 Feb;137(1):221–226. doi: 10.1016/0003-2697(84)90374-9. [DOI] [PubMed] [Google Scholar]
  10. McDivitt R. W., Stone K. R., Craig R. B., Palmer J. O., Meyer J. S., Bauer W. C. A proposed classification of breast cancer based on kinetic information: derived from a comparison of risk factors in 168 primary operable breast cancers. Cancer. 1986 Jan 15;57(2):269–276. doi: 10.1002/1097-0142(19860115)57:2<269::aid-cncr2820570214>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  11. Meyer J. S., Coplin M. D. Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors. Comparisons and correlations. Am J Clin Pathol. 1988 May;89(5):586–595. doi: 10.1093/ajcp/89.5.586. [DOI] [PubMed] [Google Scholar]
  12. Meyer J. S., Friedman E., McCrate M. M., Bauer W. C. Prediction of early course of breast carcinoma by thymidine labeling. Cancer. 1983 May 15;51(10):1879–1886. doi: 10.1002/1097-0142(19830515)51:10<1879::aid-cncr2820511021>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  13. Meyer J. S., Province M. Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat. 1988 Oct;12(2):191–204. doi: 10.1007/BF01805940. [DOI] [PubMed] [Google Scholar]
  14. Sigurdsson H., Baldetorp B., Borg A., Dalberg M., Fernö M., Killander D., Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990 Apr 12;322(15):1045–1053. doi: 10.1056/NEJM199004123221505. [DOI] [PubMed] [Google Scholar]
  15. Silvestrini R., Daidone M. G., Di Fronzo G., Morabito A., Valagussa P., Bonadonna G. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat. 1986;7(3):161–169. doi: 10.1007/BF01806246. [DOI] [PubMed] [Google Scholar]
  16. Thornthwaite J. T., Sugarbaker E. V., Temple W. J. Preparation of tissues for DNA flow cytometric analysis. Cytometry. 1980 Nov;1(3):229–237. doi: 10.1002/cyto.990010309. [DOI] [PubMed] [Google Scholar]
  17. Tubiana M., Pejovic M. H., Chavaudra N., Contesso G., Malaise E. P. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer. 1984 Apr 15;33(4):441–445. doi: 10.1002/ijc.2910330404. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES